PARP1 and breast carcinoma: For example, reactivation of HR in mammalian cells by loss of the DNA end resection inhibiting factor 53BP1 can cause resistance to PARP inhibitors (Cao et al., 2009) and has been reported in BRCA-deficient breast cancers (Bouwman et al., 2010).